Funds to help detect antibiotic resistant bacteria
€3.45 million funding available through six leading organisations, including the NIHR Devices for Dignity MedTech Co-operative
Antibiotic resistance varies according to geographic locations and is directly proportional to the use and misuse of antibiotics. Active surveillance systems, which are in place across all European member states and Norway, are to be considered one of the main contributing factors to the reduction of antimicrobials resistant organisms infections and superbugs over the years.
Through the European Union’s 2020 Horizon Anti-Superbugs Pre-Commercial Procurement project, €3.45m is being made available to develop smart ICT solutions that are able to detect the presence of resistant micro-organisms, give real-time feedback to the healthcare professional, and at the same time share the information with the healthcare provider’s electronic record systems so that the infection can be linked with the place of detection.
Once developed, these solutions could play a pivotal role in addressing the needs of healthcare providers in increasing hospital acquired infections control across the world and contribute in the development of a new stream of products in the life science and medical device industries.
The available budget for the development and testing of these innovative technologies is 3.45 million Euro (VAT included).
Successful applicants will be awarded a framework agreement that covers 3 R&D phases:
- Phase 1: Up to solution design
- Phase 2: Up to a validated prototype
- Phase 3: Up to original development, validation and testing of a limited set of first products or services, to be delivered by 31 August 2021.
All successful applicants will retain ownership of the intellectual property rights (IPRs) that they generate during the pre-commercial procurement process and will be able to use them to exploit the full market potential of the developed solutions beyond the Buyer Group.
The NIHR Devices for Dignity MedTech Co-Operative, hosted by Sheffield Teaching Hospitals NHS Foundation Trust, is one of the six leading ‘buyer groups’ who have defined what the technology will need to achieve, and will be involved in evaluating which groups should receive funding to develop the technology. This is a joint procurement involving different countries, and the state applicable national procurement law is the Spanish one.
For further information about how to submit a tender contact Katherine Jeays-Ward and check the guidance on the Anti-Superbugs Pre-Commercial Procurement website.
The deadline for submission of proposals will be on 28th October 2019